venerdì, 12 aprile 2024
8 Gennaio 2018

FDA Approves Adjuvant Pertuzumab Regimen for HER2+ Breast Cancer

December 20, 2017 – The FDA has approved pertuzumab in combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence, based on findings from the APHINITY trial. In the phase III trial, adjuvant treatment with pertuzumab, trastuzumab, and chemotherapy demonstrated a 3-year invasive disease-free survival (iDFS) rate of 94.1% versus 93.2% for those who received … (leggi tutto)